A Pilot Study of Tranilast for Cardiomyopathy of Muscular Dystrophy.
Ontology highlight
ABSTRACT: Objective Heart failure is currently the most serious complication of muscular dystrophy. The transient receptor potential cation channel, subfamily V, member 2 (TRPV2) is a stretch-sensitive Ca channel. In damaged myocytes or cardiomyocytes, TRPV2 translocates to the cytoplasmic membrane and enhances Ca influx, triggering cell damage. Evidence suggests that the inhibition of TRPV2 may be a new therapeutic target in heart failure. We found that tranilast, which is widely used as an anti-allergic drug, inhibits TRPV2. A pilot study was conducted to assess the safety and efficacy of tranilast in muscular dystrophy patients with cardiomyopathy. Methods After obtaining informed consent, two muscular dystrophy patients with advanced heart failure took tranilast (300 mg/day) for three months. Bl
SUBMITTER: Matsumura T
PROVIDER: S-EPMC5827307 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA